ArticleScientific reports2024
A hybrid in silico/in-cell controller that handles process-model mismatches using intracellular biosensing.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reinforcement Learning for Robust Dynamic Metabolic Control.Biotechnology and bioengineering · 2026Article
- Biotechnology systems engineering: preparing the next generation of bioengineers.Frontiers in systems biology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
The discrepancy between model predictions and actual processes, known as process-model mismatch (PMM), remains a substantial challenge in bioprocess optimization. We previously introduced a hybrid in silico/in-cell controller (HISICC) that combines model-based optimization with cell-based feedback to address this problem. Here, we extended this approach to regulate a key enzyme level using intracellular biosensing. The extended HISICC was implemented using an Escherichia coli strain engineered for fatty acid production (FA3). This strain contains a genetically encoded feedback controller that decelerates the expression of acetyl-CoA carboxylase (ACC) in response to malonyl-CoA synthesized through the enzymatic reaction. We modeled FA3 to allow the HISICC to optimize an inducer input that accelerates the enzyme expression. Simulations showed that the HISICC slowed the unexpectedly rapid accumulation of ACC resulting from PMMs before it reached cytotoxic levels, thereby improving fatty acid yields. These results highlight the potential of our approach, particularly in cases where monitoring intracellular biomolecules is required to handle PMMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.